A randomized, open-label study of the effect of MabThera alone and in combination with Roferon-A on time to treatment failure in patients with follicular or other low-grade lymphoma

Trial Profile

A randomized, open-label study of the effect of MabThera alone and in combination with Roferon-A on time to treatment failure in patients with follicular or other low-grade lymphoma

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Jan 2015

At a glance

  • Drugs Interferon alpha-2a (Primary) ; Rituximab (Primary)
  • Indications B cell lymphoma; Follicular lymphoma
  • Focus Registrational; Therapeutic Use
  • Sponsors Roche
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 10 Dec 2012 Results presented at the 54th Annual Meeting and Exposition of the American Society of Hematology.
    • 05 Jun 2012 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health; NCT01609010).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top